On May 15, 2019 Y-mAbs Therapeutics, Inc., (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported the acceptance of three poster presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held May 31 through June 4, 2019 in Chicago, Illinois (Press release, Y-mAbs Therapeutics, MAY 15, 2019, View Source [SID1234536435]). Two of these presentations were submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York and one was submitted by Hospital Sant Joan de Déu, Barcelona, Spain (HSJ) together with MSK.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These abstracts are publicly available online at View Source

The omburtamab abstract includes a poster presentation of

"A phase I study of convection-enhanced delivery (CED) of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma (DIPG) – An Update with Dose-Response Assessment," submitted by MSK.
The naxitamab abstracts include poster presentations of

"High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM)," submitted by MSK.
"Naxitamab-based Chemoimmunotherapy for Resistant High-Risk Neuroblastoma: Preliminary results of HITS Pilot/Phase II Study," submitted by HSJ together with MSK.